Surgical resection is the traditional treatment for hepatic hemangioma, which has the disadvantages of large trauma, many potential complications and limited application. In the past 10 years or so, some hepatobiliary surgery experts have devoted themselves to applying radiofrequency ablation to the clinical treatment of hepatic hemangioma and achieved satisfactory milestones, proposing important ideas such as radiofrequency ablation can be the preferred treatment modality for hepatic hemangioma, and summarizing a series of safety strategies. The relevant results have been published in the American Journal of Surgery and Clinical Gastroenterology, indicating that the research results in this field have been widely recognized by international colleagues. I. Hepatic hemangioma needs active treatment if it is larger than 5 cm in size and has an obvious tendency to grow Hepatic hemangioma is the most common benign tumor of the liver. Most hepatic hemangiomas are less than 5 cm in diameter and grow slowly, so no special treatment is needed and regular observation is sufficient. If the diameter of hemangioma is larger than 5 cm and the tendency of tumor growth is obvious, or if the tumor increases to the point of producing clinical symptoms such as abdominal distension and stomach distension, active treatment is needed. In the past, surgical resection was almost the only treatment for hepatic hemangioma, but this treatment method is very traumatic and has many complications. The literature reports that the complication rate of surgical treatment of hepatic hemangioma is 27% and the morbidity and mortality rate is 3%. For a benign disease, surgical treatment has such a high complication rate and morbidity and mortality that it is difficult for both clinicians and patients to accept easily. In the last decade, surgeons and interventionalists have been trying to apply radiotherapy and hepatic artery interventional embolization to treat hepatic hemangiomas. However, these two local treatment options may produce more serious complications such as intrahepatic bile duct injury, ectopic embolism, radioactive hepatitis and veno-occlusive disease, which are contrary to the concept of minimally invasive treatment and difficult to be widely accepted. Radiofrequency ablation is minimally invasive, safe and effective, and can be the preferred treatment option for hepatic hemangioma Radiofrequency ablation is a common minimally invasive treatment modality for liver malignant tumors, and is one of the curative means for early liver cancer. The main principle is to generate enough heat through radiofrequency current to cause coagulative necrosis of tumor tissues. In the past decade, radiofrequency ablation has been applied experimentally to the treatment of hepatic hemangioma, which initially showed the advantages of being minimally invasive, safe and effective. The cases reported in the literature in which radiofrequency ablation was applied were mostly large hepatic hemangiomas of 5 to 10 cm, and there were fewer reports of treatment of giant hemangiomas over 10 cm. in 2011, an article published in the Journal of Hepatology included 20 large hemangiomas and 5 giant hepatic hemangiomas treated with radiofrequency ablation; as a result, 2 of the 5 giant hepatic hemangiomas failed to be treated. Therefore, the authors of the article concluded that radiofrequency ablation is not suitable for the treatment of giant hepatic hemangiomas. We summarized the cases treated before 2010 and the results showed that radiofrequency ablation can safely and effectively treat large hepatic hemangiomas, but the treatment of giant hepatic hemangiomas, although satisfactory, has a high complication rate, which, of course, is mostly due to the inexperience when the work was initially performed. The results of this study were published in the prestigious American Journal of Surgery. Patients with hepatic hemangioma in China lack regular medical checkups and are often diagnosed only when the tumor has progressed to a large size and developed clinical symptoms, which is significantly different from developed countries. Patients with giant hepatic hemangioma, in turn, are often treated by doctors and patients who usually put off treatment again and again due to the huge size of the tumor and the risk of surgery, delaying the best time for treatment. In this perspective, giant hepatic hemangioma is a category of disease that requires more minimally invasive treatment. Based on our previous work, our team has conducted research to address the problem of excessive complications of radiofrequency ablation for giant hepatic hemangioma; by changing the treatment concept, improving the treatment strategy, and upgrading the ablation equipment, we have significantly reduced ablation-related complications. First, when treating giant hepatic hemangioma, we no longer force to achieve complete ablation at one time for the characteristics of benign disease, and we can choose to repeat RF ablation strategy when necessary. Second, we proposed a series of ablation strategies, including ablation electrodes to enter hepatic hemangioma through normal liver tissue, appropriately prolonging the ablation time of the first ablation point, adopting the multi-point ablation strategy of “edge first, then center”, and intermittently blocking the first hepatic portal blood flow under the laparoscopic path. Thirdly, comparing various ablation electrodes, we believe that the cold circulation, straight needle design ablation electrode is more suitable for ablation of hepatic hemangioma due to its features of concentrated functional release and no coking of the tissue around the needle. The above work was recognized by international colleagues and was published in the American Journal of Clinical Gastroenterology. In conclusion, the treatment principle of hepatic hemangioma is changing from the traditional surgical treatment to the minimally invasive treatment modality represented by radiofrequency ablation, which can be the preferred modality for the treatment of hepatic hemangioma.